Published in Appl Immunohistochem Mol Morphol on September 01, 2007
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat (2014) 1.08
PELP1 oncogenic functions involve CARM1 regulation. Carcinogenesis (2013) 0.99
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study. BMC Cancer (2015) 0.85
PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res (2015) 0.84
Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Sci Rep (2015) 0.82
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab (2016) 0.78
A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. Mod Pathol (2016) 0.78
Uncaria tomentosa-Adjuvant Treatment for Breast Cancer: Clinical Trial. Evid Based Complement Alternat Med (2012) 0.78
SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. Am J Cancer Res (2016) 0.78
ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors. Cancer Cell Int (2016) 0.77
An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Virchows Arch (2016) 0.77
ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy. PLoS One (2014) 0.75
Modeling Canadian Quality Control Test Program for Steroid Hormone Receptors in Breast Cancer: Diagnostic Accuracy Study. Appl Immunohistochem Mol Morphol (2015) 0.75
Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort. Mod Pathol (2016) 0.75
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. World J Surg Oncol (2016) 0.75
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst (2002) 4.09
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (2007) 3.07
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol (2004) 2.39
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol (2006) 2.24
Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol (2003) 2.20
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res (2003) 2.01
Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol (2002) 1.99
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res (2004) 1.89
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer (2003) 1.87
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw (2009) 1.73
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res (2006) 1.67
Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med (2010) 1.64
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A (2006) 1.60
The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res (2008) 1.59
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Lobular neoplasia on core-needle biopsy--clinical significance. Cancer (2004) 1.57
Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol (2012) 1.53
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol (2011) 1.43
Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res (2006) 1.43
Invasive breast cancer. J Natl Compr Canc Netw (2011) 1.43
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res (2004) 1.42
Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J (2002) 1.42
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol (2007) 1.25
Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res (2012) 1.23
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.23
Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res (2005) 1.23
Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg (2005) 1.20
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer (2003) 1.18
Defensin-rich granules of human neutrophils: characterization of secretory properties. Biochim Biophys Acta (2002) 1.14
The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys (2004) 1.13
Localization of serglycin in human neutrophil granulocytes and their precursors. J Leukoc Biol (2004) 1.09
Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology (2005) 1.06
Steroid receptor coactivator 2 is required for female fertility and mammary morphogenesis: insights from the mouse, relevance to the human. Nucl Recept Signal (2007) 1.06
Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin Cancer Res (2013) 1.01
Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate (2004) 0.97
Independent validation of a model using cell line chemosensitivity to predict response to therapy. J Natl Cancer Inst (2013) 0.92
Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med (2006) 0.91
Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat (2005) 0.90
FGFR1 amplification and the progression of non-invasive to invasive breast cancer. Breast Cancer Res (2012) 0.89
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat (2005) 0.88
The estrogen paradox. Nat Clin Pract Endocrinol Metab (2007) 0.87
"Dwarf" estrogen receptor in breast cancer and resistance to tamoxifen. J Clin Oncol (2009) 0.86
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat (2009) 0.85
Steroid receptor coactivator 2 is essential for progesterone-dependent uterine function and mammary morphogenesis: insights from the mouse--implications for the human. J Steroid Biochem Mol Biol (2006) 0.85
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat (2005) 0.83
Pathologic outcomes of nonmalignant papillary breast lesions diagnosed at imaging-guided core needle biopsy. Radiology (2012) 0.82
Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone. J Natl Cancer Inst (2010) 0.82
Progesterone-action in the murine uterus and mammary gland requires steroid receptor coactivator 2: relevance to the human. Front Biosci (2007) 0.80
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat (2005) 0.79
Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol (2008) 0.79
Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw (2010) 0.78
Dumbbell Defects in FeSe Films: A Scanning Tunneling Microscopy and First-Principles Investigation. Nano Lett (2016) 0.78
Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol (2008) 0.77
Intra-mammary ductal transplantation: a tool to study premalignant progression. J Mammary Gland Biol Neoplasia (2012) 0.77
Re: The influence of menstrual cycle phase on surgical treatment of primary breast cancer: have we made any progress over the past 13 years? J Natl Cancer Inst (2002) 0.75
Fixation time does not affect expression of HER2/neu. Am J Clin Pathol (2011) 0.75
ER expression is not bimodal in breast cancer. Am J Clin Pathol (2005) 0.75
Nanoscale interplay of strain and doping in a high-temperature superconductor. Nano Lett (2014) 0.75